Introduction {#s1}
============

Diabetic nephropathy (DN) is the most common microvascular complication of diabetes with persistent microalbuminuria, renal tubules, and renal interstitial fibrosis as its main clinical features ([@B15]). Its incidence is 25%−40% in patients affected with type 1 diabetes, whereas it is 5%--40% in those with type 2 diabetes ([@B2]). Patients with DN have increased risks of coronary heart disease, stroke, and peripheral artery disease. Approximately 50% of DN patients worldwide eventually reach end-stage renal disease (ESRD) without effective treatment ([@B36]; [@B20]). Hyperglycemia is the main driving force of DN, causing kidney damage either directly or through hemodynamic changes ([@B37]). Moreover, hypertension, dyslipidemia, elevated uric acid, obesity, and smoking accelerate DN progression ([@B39]). Its pathogenesis may be linked to renal hyperfiltration and renal injury, glucose metabolic disorder, vasoactive substances, and heredity ([@B4]). Chronic inflammatory response and oxidative stress also play important roles on DN and have become appropriate targets for therapeutic intervention ([@B41]; [@B10]). According to Mogensen Stage, DN can be divided into five stages. Most patients were diagnosed in stage III or after stage III, because the symptoms were unconspicuous when in stage I and II ([@B3]). Once DN enters to end stage (stage V), of which treatment would be more difficult than other kidney diseases ([@B9]). In consequence, interventions for delaying DN progression and improving the condition become particularly important. Currently, the key to treating DN is intensive glycemic control, and thus new antidiabetic drugs with specific renal protective effects are widely used in clinical practice ([@B32]). Previous studies have discovered two major classes of antihypertensive drugs, i.e., angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which are available to slow down renal disease progression by controlling albuminuria ([@B1]). In spite of tremendous advances in the pharmaceutical drug industry, the condition of renal function in DN patients and the side effects of some drugs have restricted the clinical application of western medicine ([@B46]). Thus, more novel and effective therapies should be seeked beyond active symptomatic treatment for patients affected with DN.

Traditional Chinese medicine (TCM), as therapeutic alternatives, has shown unique advantages on DN, owing to its characteristics of multicomponents and multitargets ([@B34]). *Salvia miltiorrhiza*, a famous Chinese herb, has been mentioned in the oldest Chinese book of material medica "Shennong Herbal Classic" with the reputation of "one *Salvia miltiorrhiza*, the same function as Siwu decoction". Salvianolate is a compound preparation extracted from *salvia miltiorrhiza*, which mainly consists of salvia magnesium acetate (3 molecules of 3,4-dihydroxyphenyllactic acid and 1 molecule of caffeic acid, 80%) and homologous compounds (magnesium shikonate, sodium rosemary, salvia dipotassium acetate, potassium salvia, and dipotassium shikonate, 20%) ([@B42]; [@B21]). As a water-soluble ingredient, salvianolate possesses typical bioactivities such as protecting renal function, promoting microcirculation, scavenging oxygen free radicals, and improving vascular endothelial function ([@B38]; [@B50]). Furthermore, it has been reported that salvianolate could treat atherosclerosis *via* regulating the inflammation at cytokine and cell levels ([@B30]); it could improve cerebral ischemic injury and the mechanism may be related to the activation of the vascular endothelial growth factor (VEGF) and BDNF-TrkB-CREB signaling pathway ([@B16]); it protected hepatocytes from oxidative stress by attenuating mitochondrial injury ([@B55]). Hence, salvianolate has been shown to have significant efficacy in various diseases.

Recently, numerous clinical studies have identified the benefits of salvianolate in the treatment of DN. In animal models, [@B35] showed that its application improved the levels of urine protein and serum creatinine, and changed the activity of lactate dehydrogenase (LDH) and superoxide dismutase (SOD), thereby indicating protective effects on renal function. However, there is still short of systematic evidence to confirm its clinical effect. Thus, we conducted a meta-analysis to evaluate the efficacy and safety of salvianolate as a complementary therapy to treat DN.

Materials and Methods {#s2}
=====================

Literature Selection {#s2_1}
--------------------

The following electronic databases were searched: Pubmed, Web of Science, the Cochrane Library, China National Knowledge Infrastructure(CNKI), Wanfang Data knowledge service platform (Wanfang Data), Chinese Scientific Journal Database (VIP), and China Biology Medicine Disc (SinoMed). The retrieval time was from the creation of each database until November 30, 2019. To avoid omission, the retrieval scheme contained subject words with free words, keywords, or full text. We searched Chinese words such as "Danshenduofensuanyan", "Danshenduofensuanyan Injection", "Tangniaobing Shenbing", "Tangniaobing Shensunhai", and English words such as "Salvianolate", "Salvia Polyphenola", "Salvia Miltiorrhiza Polyphenolate", "Diabetic Nephropathy", "Diabetic Kidney Disease", "Diabetic Renal Damage", "DN", and "DKD" ([**Supplementary Tables 1**](#SM1){ref-type="supplementary-material"} and [**2**](#SM1){ref-type="supplementary-material"}). The retrieval language was restricted to Chinese and English. We also used manual searches to ensure the integrity of the included studies.

Inclusion Criteria {#s2_2}
------------------

Studies should meet the criteria as follows: (1) Patients were diagnosed with DN based on the World Health Organization (WHO) diagnostic standard and Mogensen staging criteria ([@B31]; [@B14]), with the exclusion of those with primary kidney diseases, systemic infectious diseases, malignant tumors, and other serious organ dysfunction diseases; (2) The treatment group was administered salvianolate injection combined with conventional treatment; (3) The control group was given conventional treatment including lifestyle changes, interventions of diet habits, administration of hypoglycemic drugs, control of blood pressure, and regulation of dyslipidemia; (4) One or some related outcomes, including renal function (serum creatinine, blood urea nitrogen, urinary albumin excretion rate, 24-hour urinary protein, and albumin-to-creatinine ratio), inflammatory factors (hypersensitive C-reactive protein and Interleukin-6), oxidative stress indicators (malondialdehyde and superoxide dismutase), clinical efficacy, and adverse reactions were reported in the studies; (5) Only published randomized controlled trials (RCTs) were included, irrespective of blinding; (6) Remedy in the two groups continued for 2 weeks or longer; (7) Salvianolate was provided by Shanghai Green Valley Pharmaceutical Co., Ltd (Shanghai, China).

Exclusion Criteria {#s2_3}
------------------

The following studies were excluded: (1) those that were unpublished; (2) those with non-randomized controlled trials or significant defect in experimental design; (3) annimal experiments, case reports, reviews, or experience summaries; (4) those with inconsistency in conventional therapies given in the two groups; and (5) those that failed to obtain the sufficient available data.

Quality Evaluation {#s2_4}
------------------

Methodological quality was evaluated using the bias risk assessment tool from Cochrane Handbook (version 5.0), which includes the following 6 aspects: (1) random allocation methods; (2) allocation concealment; (3) blinding; (4) integrity of outcome data; (5) selective reporting; and (6) other sources of bias. All the above were classified as "low risk", "high risk", or "unclear risk" ([@B49]).

Data Extraction {#s2_5}
---------------

Two evaluators independently screened the collected studies based on the inclusion and exclusion criteria previously mentioned. According to the pre-designed data extraction form, the relevant information collected were title, author's name, publication year, research object, research method, treatment intervention, outcomes, and adverse reactions. Any disagreement during evaluation was solved by negotiation. If such disagreement was not resolved, a third researcher joined the discussion and made the final decision.

Data Analysis {#s2_6}
-------------

RevMan5.3 provided by the Cochrane collaboration network was used to perform statistical analysis for this meta-analysis ([@B27]). The selection of effect quantity includes the following: (1) Risk ratio (RR) was chosen as the dichotomous variable; (2) Mean difference (MD) and the standard mean difference (SMD) were expressed as the continuous variables; and (3) 95% confidence interval (CI) was used for interval estimation. Heterogeneity was determined using chi-squared test and the I^2^ statistic. If I^2^ was less than 50%, it represented homogeneity and a fixed effect model was selected. Otherwise, a random effect model was used, and the heterogeneity of the included studies should be analyzed. Subgroup analysis based on the research characteristics was carried out to explore the source of heterogeneity. Moreover, sensitivity analysis was used to assess the stability of the meta-analysis results. If the number of included studies were more than ten, potential publication bias will be detected using funnel plot. The *P-*value less than 0.05 was considered statistically significant.

Results {#s3}
=======

Search Results {#s3_1}
--------------

Initially, 387 articles were obtained. We used the Endnote software for document management, and 164 duplicated articles were eliminated. From the title and abstract, 179 articles were excluded because they were irrelevant studies (n=142), case reports (n=10), traditional reviews (n=9), and basic experiments (n=18). After assessing the full texts carefully, 32 out of the remaining 44 articles were removed, which included non-randomized control trials (n=6), trials with incomplete data (n=2), studies not focusing on salvianolate (n=18), and other documents (n=6). Finally, 12 articles ([@B46]; [@B23]; [@B26]; [@B48]; [@B51]; [@B28]; [@B53]; [@B54]; [@B7]; [@B13]; [@B8]; [@B22]) were included for the meta-analysis. The screening process is presented in [**Figure 1**](#f1){ref-type="fig"}.

![Flow diagram of literature screening.](fphar-11-00851-g001){#f1}

Study Characteristics and Quality Evaluation {#s3_2}
--------------------------------------------

From the 12 randomized controlled trials ([@B46]; [@B23]; [@B26]; [@B48]; [@B51]; [@B28]; [@B53]; [@B54]; [@B7]; [@B13]; [@B8]; [@B22]) selected, there were 1,030 patients with 514 in the control group and 516 in the treatment group. The basic characteristics of the 12 RCTs are summarized in [**Table 1**](#T1){ref-type="table"}. The methodological quality of the studies included was low. Although all the studies used random grouping, only 6 ([@B26]; [@B28]; [@B53]; [@B54]; [@B8]; [@B22]) described the specific grouping methods. None of the studies reported blinding or allocation concealment. The quality assessment is shown in [**Figure 2**](#f2){ref-type="fig"}.

###### 

Basic characteristics of inclusion in the study.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study    Sample size   Sex         Age(Years)         Duration of        Course of   Intervention                                                           Outcomes                            Adverse                                                              
  -------- ------------- ----------- ------------------ ------------------ ----------- ---------------------------------------------------------------------- ----------------------------------- -------------------------------------------------------------------- --------------------------------------------
  [@B46]   30/30         T: 17/13\   T: 55.8 ± 7.4\     T: 7.7 ± 1.7\      3 weeks     Salvianolate (200 mg, ivgtt, qd)+ conventional treament                Conventional treament               Scr, UAER                                                            None
                         C: 18/12    C: 56.5 ± 7.3      C: 7.6 ± 1.8                                                                                                                                                                                                   

  [@B51]   45/45         50/40       T: 48.9 ± 10.1\    T: 8.49 ± 1.6\     2 weeks     Salvianolate (100 mg, ivgtt, qd)+ conventional treament                Conventional treament               SOD, MDA, ACR                                                        Not reported
                                     C: 49.4 ± 9.6      C: 8.51 ± 1.4                                                                                                                                                                                                  

  [@B48]   30/30         T: 18/12\   T: 56.34 ± 6.06\   T: 6.25 ± 5.07\    4 weeks     Salvianolate (200 mg, ivgtt, qd)+ conventional treament                Conventional treament               Scr, UAER                                                            Not reported
                         C: 19/11    C: 55.81 ± 7.24    C: 6.69 ± 4.62                                                                                                                                                                                                 

  [@B23]   30/30         T: 14/16\   T: 65.12 ± 9.83\   T: 12.91 ± 2.12\   2 weeks     Salvianolate (200 mg, ivgtt, qd)+ conventional treament                Conventional treament               Scr, BUN, UAER                                                       T: 1 case of Palpitations during infusion\
                         C: 17/13    C: 65.4 ± 9.6      C: 12.42 ± 2.28                                                                                                                                                                                                C: None

  [@B26]   33/31         T: 16/17\   T: 56.16 ± 9.09\   --\                2 weeks     Salvianolate (200 mg, ivgtt, qd)+ Insulin therapy                      Insulin therapy                     hs-CRP, IL-6                                                         Not reported
                         C: 16/15    C: 54.70 ± 9.26    --                                                                                                                                                                                                             

  [@B54]   45/45         T: 24/21\   T: 63.4 ± 9.80\    T: 7.1 ± 2.4\      4 weeks     Salvianolate (200 mg, ivgtt, qd)+ conventional treament                Conventional treament               Scr, BUN, UAER, Clinical efficacy                                    None
                         C: 24/21    C: 63.0 ± 11.1     C: 7.3 ± 1.4                                                                                                                                                                                                   

  [@B53]   42/42         T: 23/19\   T: 39\~72\         T: 5.8 ± 1.4\      2 weeks     Salvianolate (200 mg, ivgtt, qd)+ conventional treament                Conventional treament               UAER, hs-CRP, IL-6                                                   Not reported
                         C: 25/17    C: 41\~71          C: 5.7 ± 1.1                                                                                                                                                                                                   

  [@B28]   59/59         T: 29/30\   T: 53\~78\         T: 12.3 ± 3.8\     2 weeks     Salvianolate (200 mg, ivgtt, qd)+ conventional treament                Conventional treament               hs-CRP, IL-6                                                         Not reported
                         C: 27/32    C: 51\~79          C: 12.5 ± 2.8                                                                                                                                                                                                  

  [@B13]   38/38         T: 22/16\   T: 45\~75\         T: 5.98 ± 2.27\    2 weeks     Salvianolate (100 mg, ivgtt, qd)+ Irbesartan (150 mg, po, qd)          Irbesartan (150mg, po, qd)          Scr, BUN, Clinical efficacy, hs-CRP, IL-6, MDA, SOD, 24h Upro, ACR   None
                         C: 18/20    C: 42\~74          C: 6.04 ± 2.03                                                                                                                                                                                                 

  [@B7]    60/60         T: 39/21\   T: 68.82 ± 8.63\   T: 6.54 ± 2.64\    2 weeks     Salvianolate (200 mg, ivgtt, qd)+ Losartan potassium (50 mg, po, qd)   Losartan potassium (50mg, po, qd)   Scr, BUN, Clinical efficacy, hs-CRP, IL-6, 24h Upro                  Not reported
                         C: 38/22    C: 68.45 ± 8.35    C: 6.65 ± 2.15                                                                                                                                                                                                 

  [@B22]   47/47         T: 27/20\   T: 57.34 ± 6.28\   T: 4.87 ± 2.41\    2 weeks     Salvianolate (200 mg, ivgtt, qd)+ Irbesartan (150 mg, po, qd)          Irbesartan (150mg, po, qd)          Scr, BUN, Clinical efficacy, SOD, MDA, 24h Upro                      Not reported
                         C: 26/21    C: 57.15 ± 6.34    C: 4.95 ± 2.36                                                                                                                                                                                                 

  [@B8]    57/57         T: 33/24\   T: 58.41 ± 3.87\   T: 4.93 ± 1.21\    2 weeks     Salvianolate (200 mg, ivgtt, qd)+ conventional treament                conventional treament               Scr, BUN, Clinical efficacy, UAER                                    None
                         C: 34/23    C: 57.25 ± 3.64    C: 4.85 ± 1.12                                                                                                                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

T, treatment group; C, control group; M, male; F, female; Scr, serum creatinine; UAER, urinary albumin excretion rate; BUN, blood urea nitrogen; SOD, superoxide dismutase; MDA, malondialdehyde; hs-CRP, hypersensitive C-reactive protein; IL-6, Interleukin-6; 24h Upro, 24-hour urinary protein; ACR, albumin-to-creatinine ratio.

![Graphs for risk of bias.](fphar-11-00851-g002){#f2}

Outcomes {#s3_3}
--------

### Effect on Renal Function {#s3_3_1}

#### Serum Creatinine (Scr) {#s3_3_1_1}

Eight RCTs measured Scr levels ([@B46]; [@B23]; [@B48]; [@B54]; [@B7]; [@B13]; [@B8]; [@B22]) to assess the renal function in DN patients. After heterogeneity test (*P* \< 0.1, I^2^ = 98%), a random effect model was used to pool the data. The meta-analysis indicated that the intervention of salvianolate combined with western medicine performed better than using western medicine alone in terms of decreased Scr levels \[MD=--16.53, 95% CI (--28.79, --4.27), Z=2.64, *P*=0.008\] ([**Figure 3A**](#f3){ref-type="fig"}).

![Forest plot for serum creatinine (Scr) between the treatment group and control group **(A)**. Forest plot for blood urea nitrogen (BUN) between the treatment group and control group **(B)**.](fphar-11-00851-g003){#f3}

#### Blood Urea Nitrogen (BUN) {#s3_3_1_2}

Six studies ([@B23]; [@B54]; [@B7]; [@B13]; [@B8]; [@B22]) assessed the BUN levels of DN patients. Due to significant heterogeneity (*P* \< 0.1, I^2^ = 84%), a random effect model was chosen to pool the data. The results showed that patients with salvianolate plus western drugs demonstrated significantly decreased BUN levels than those with western drugs alone \[MD=--1.40, 95% CI (--2.17, --0.62), Z=3.52, *P*=0.0004\] ([**Figure 3B**](#f3){ref-type="fig"}).

#### Urinary Albumin Excretion Rate (UAER) {#s3_3_1_3}

Six studies ([@B46]; [@B23]; [@B48]; [@B53]; [@B54]; [@B8]) reported UAER in the treatment of DN. Because of high heterogeneity (*P* \< 0.1, I^2^ = 93%), a random effect model was adopted to pool the data. The meta-analysis revealed that compared with the control group, the application of salvianolate combined with western medicine had more significantly reduced UAER \[SMD=--1.84, 95% CI (--2.70, --0.98), Z=4.19, *P* \< 0.0001\] ([**Figure 4**](#f4){ref-type="fig"}).

![Forest plot for urinary albumin excretionrate (UAER) between the treatment group and control group.](fphar-11-00851-g004){#f4}

#### 24-h Urinary Protein (24h Upro) {#s3_3_1_4}

Three studies ([@B7]; [@B13]; [@B22]) showed 24h Upro results of DN patients. With the result of homogeneity after test (*P*=0.54, I^2^ = 0%), we chose a fixed effect model. The meta-analysis suggested that salvianolate combined with western medicine was more effective than the control group in decreasing 24h Upro \[MD=--0.37, 95% CI (--0.47, --0.26), Z=6.95, *P* \< 0.00001\] ([**Figure 5A**](#f5){ref-type="fig"}).

![Forest plot for 24-hour urinary protein (24h Upro) between the treatment group and control group **(A)**. Forest plot for albumin-to-creatinine ratio (ACR) between the treatment group and control group **(B)**.](fphar-11-00851-g005){#f5}

#### Albumin-to-Creatinine Ratio (ACR) {#s3_3_1_5}

Only two studies ([@B51]; [@B13]) out of twelve reported the ratio of ACR at the end of the treatment. Because of high heterogeneity (*P* \< 0.1, I^2^ = 91%), a random effect model was selected to pool the data. The meta-analysis revealed that compared with the control group, patients with salvianolate plus western drugs showed more advantages in reducing the ratio of ACR \[SMD=--1.43, 95% CI (--2.64, --0.23), Z=2.34, *P*=0.02\] ([**Figure 5B**](#f5){ref-type="fig"}).

### Effect on Inflammatory Factors {#s3_3_2}

#### Hypersensitive C-Reactive Protein (hs-CRP) {#s3_3_2_1}

A total of five studies ([@B26]; [@B28]; [@B53]; [@B7]; [@B13]) measured hs-CRP levels. Because of moderate heterogeneity (*P* \< 0.1, I^2^ = 56%), a random effect model was adopted for data analysis. The meta-analysis indicated that hs-CRP levels in patients treated with salvianolate plus western drugs were significantly lower than those in the control group \[MD=--5.69, 95% CI (--7.09, --4.29), Z=7.99, *P* \< 0.00001\] ([**Figure 6A**](#f6){ref-type="fig"}).

![Forest plot for hypersensitive C-reactive protein (hs-CRP) between the treatment group and control group **(A)**. Forest plot for interleukin-6 (IL-6) between the treatment group and control group **(B)**.](fphar-11-00851-g006){#f6}

#### Interleukin-6 (IL-6) {#s3_3_2_2}

A total of five studies ([@B26]; [@B28]; [@B53]; [@B7]; [@B13]) reported IL-6 results. Because of high heterogeneity (*P* \< 0.1, I^2^ = 96%), a random effect model was used for data analysis. The meta-analysis showed significantly decreased levels of IL-6 in salvianolate combined with western medicine compared with the single-use western medicine \[MD=--12.53, 95% CI (--18.55, --6.52), Z=4.09, *P* \< 0.0001\] ([**Figure 6B**](#f6){ref-type="fig"}).

### Effect on Oxidative Stress Indicators {#s3_3_3}

#### Superoxide Dismutase (SOD) {#s3_3_3_1}

There were three studies ([@B51]; [@B13]; [@B22]) that assessed SOD levels. With the result of homogeneity after test (*P*=0.56, I^2^ = 0%), we chose a fixed effect model. The meta-analysis demonstrated that compared with the control group, significantly increased SOD levels were observed in salvianolate plus western drugs \[SMD=1.12, 95% CI (0.86, 1.38), Z=8.35, *P* \< 0.00001\] ([**Figure 7A**](#f7){ref-type="fig"}).

![Forest plot for superoxide dismutase (SOD) between the treatment group and control group **(A)**. Forest plot for malondialdehyde (MDA) between the treatment group and control group **(B)**.](fphar-11-00851-g007){#f7}

#### Malondialdehyde (MDA) {#s3_3_3_2}

There were three studies ([@B51]; [@B13]; [@B22]) that measured MDA levels. Because of considerable heterogeneity (*P* \< 0.1, *I^2^ =* 96%), a random effect model was adopted for data analysis. The meta-analysis revealed that the combination treatment of salvianolate and western medicine had more significantly reduced MDA levels compared with western medicine monotherapy \[SMD=--2.05, 95% CI (--3.67, --0.43), Z=2.48, *P*=0.01\] ([**Figure 7B**](#f7){ref-type="fig"}).

Clinical Efficacy {#s3_4}
-----------------

Five of the 12 studies ([@B54]; [@B7]; [@B13]; [@B8]; [@B22]) evaluated clinical efficacy. With the result of homogeneity after test (*P*=0.26, I^2^ = 25%), we used a fixed effect model. The meta-analysis demonstrated that the combination of salvianolate and western medicine was superior to the single-use western medicine in improving clinical efficacy \[RR=1.21, 95% CI (1.12,1.31), Z=4.62, *P* \< 0.00001\] ([**Figure 8**](#f8){ref-type="fig"}).

![Forest plot for clinical efficacy between the treatment group and control group.](fphar-11-00851-g008){#f8}

Adverse Reactions {#s3_5}
-----------------

Five out of the 12 trials ([@B46]; [@B23]; [@B54]; [@B13]; [@B8]) described adverse reactions. Only one ([@B23]) reported a case with palpitation during salvianolate injection, and the symptoms of which disappeared after adjusting the infusion rate. The other four trials ([@B46]; [@B54]; [@B13]; [@B8]) found no adverse reactions in the treatment group or control group. However, because the remaining trials did not provide any details on adverse effects, the safety of salvianolate still needs to be treated with caution in the future.

Subgroup Analysis {#s3_6}
-----------------

According to the stage of Mogensen, we excluded the study ([@B7]) since they did not clearly provide the staging results of DN patients. And the remaining 11 RCTs were divided into two subgroups: stage III group ([@B46]; [@B23]; [@B26]; [@B48]; [@B51]; [@B28]; [@B53]; [@B54]), and stage III-IV group ([@B13]; [@B22]; [@B8]). To explore the source of heterogeneity, subsequent subgroup analyses were conducted for Scr, BUN and UAER, as they were crucial indicators on the evauation of renal function. The pooled data are shown in [**Table 2**](#T2){ref-type="table"}. The results indicated significant differences between the group treated with salvianolate plus western drugs and that with single-use western drugs for each subgroup in terms of the stage of DN ([**Supplementary Figures 1--3**](#SM1){ref-type="supplementary-material"}). However, for Scr, there was no significant difference in stage III \[MD=--0.97, 95% CI (--5.32, 3.38), *P*=0.66\]. Meanwhile, the declined heterogeneity on Scr and BUN demonstrated that the stage of DN may be a cause of heterogeneity. Nevertheless, for UAER, the heterogeneity was not removed from subgroup analysis.

###### 

Subgroup analyses for Scr, BUN, and UAER.

  Outcome   Stage of DN    n   MD/SMD(95% CI)               I^2^(%)          Z       *P*
  --------- -------------- --- ---------------------------- ---------------- ------- -----------
  Scr       stage III      4   --0.97 (--5.32,3.38)         44               0.44    0.66
            stage III-IV   3   --21.31 (--23.38, --19.25)   0                20.21   \<0.00001
  BUN       stage III      2   --0.46 (--0.90, --0.01)      0                2.01    0.04
            stage III-IV   3   --1.29 (--1.90, --0.68)      67               4.16    \<0.0001
  UAER      stage III      5   --1.96 (--3.09, --0.83)      95               3.40    0.0007
            stage III-IV   1   --1.34 (--1.75, --0.93)      Not applicable   6.45    \<0.00001

Scr, serum creatinine; BUN, blood urea nitrogen; UAER, urinary albumin excretion rate.

Sensitivity Analysis {#s3_7}
--------------------

Sensitivity analyses were carried out for outcomes with heterogeneity by removing the included studies one by one, to observe whether the results were significantly changed ([**Table 3**](#T3){ref-type="table"}). We found that heterogeneity still existed and the outcomes after the removal of each study were similar, indicating that the results were not affected by any individual study and had relatively good stability, except for hs-CRP results of [@B28] and MDA results of [@B22]. For hs-CRP results, heterogeneity dropped from 56% to 0% when the study [@B28] was excluded. Therefore, this RCT may be a source of considerable heterogeneity. One of the possible explanations would be the longest course of disease that influenced the sensitivity to drugs during treatment. For MDA results, the *P*-value greater than 0.05 became insignificant when the study [@B22] was eliminated. Despite the overall significant *P*-value, the results of MDA were not robust enough and need to be further verified.

###### 

Sensitivity analyses for Scr, BUN, UAER, ACR, hs-CRP, IL-6, and MDA.

  Outcome   Study    Data with study removed                               
  --------- -------- ---------------------------- ---------------- ------- -----------
  Scr                                                                      
            [@B46]   --22.17 (--23.94, --20.41)   97               24.67   \<0.00001
            [@B48]   --17.74 (--19.33, --16.15)   98               21.88   \<0.00001
            [@B23]   --18.45 (--20.08, --16.82)   98               22.21   \<0.00001
            [@B54]   --17.18 (--18.76, --15.61)   98               21.40   \<0.00001
            [@B13]   --15.65 (--17.45, --13.84)   98               16.99   \<0.00001
            [@B7]    --13.40 (--15.04, --11.76)   96               16.02   \<0.00001
            [@B22]   --15.45 (--17.32, --13.58)   98               16.19   \<0.00001
            [@B8]    --17.06 (--18.64, --15.48)   98               21.16   \<0.00001
  BUN                                                                      
            [@B23]   --1.49 (--2.32, --0.65)      87               3.48    0.0005
            [@B54]   --1.66 (--2.54, --0.77)      81               3.66    0.0003
            [@B13]   --1.34 (--2.27, --0.42)      84               2.84    0.005
            [@B7]    --1.03 (--1.62, --0.44)      74               3.45    0.0006
            [@B22]   --1.44 (--2.42, --0.45)      87               2.85    0.004
            [@B8]    --1.62 (--2.58, --0.66)      87               3.32    0.0009
  UAER                                                                     
            [@B46]   --1.52 (--2.32, --0.71)      92               3.71    0.0002
            [@B48]   --2.17 (--3.01, --1.34)      91               5.10    \<0.00001
            [@B23]   --1.54 (--2.36, --0.72)      92               3.68    0.0002
            [@B54]   --2.00 (--3.09, --0.92)      95               3.61    0.0003
            [@B53]   --1.86 (--2.92, --0.80)      95               3.45    0.0006
            [@B8]    --1.96 (--3.09, --0.83)      95               3.40    0.0007
  ACR                                                                      
            [@B51]   --2.06 (--2.62, --1.50)      Not applicable   7.20    \<0.00001
            [@B13]   --0.83 (--1.27, --0.40)      Not applicable   3.79    0.0002
  hs-CRP                                                                   
            [@B26]   --5.43 (--6.94, --3.92)      56               7.05    \<0.00001
            [@B53]   --5.98 (--7.73, --4.24)      67               6.72    \<0.00001
            [@B28]   --6.34 (--7.58, --5.11)      0                10.05   \<0.00001
            [@B13]   --5.52 (--7.14, --3.90)      59               6.68    \<0.00001
            [@B7]    --5.34 (--6.75, --3.94)      51               7.46    \<0.00001
  IL-6                                                                     
            [@B26]   --10.05 (--15.30, --4.79)    93               3.75    0.0002
            [@B53]   --13.16 (--20.66, --5.67)    97               3.44    0.0006
            [@B28]   --11.77 (--19.79, --3.75)    96               2.88    0.004
            [@B13]   --14.60 (--19.98, --9.22)    93               5.32    \<0.00001
            [@B7]    --13.12 (--20.33, --5.92)    96               3.57    0.0004
  MDA                                                                      
            [@B51]   --2.78 (--5.33, --0.23)      97               2.14    0.03
            [@B13]   --1.07 (--1.91, --0,22)      86               2.48    0.01
            [@B22]   --2.36 (--5.75,1.04)         98               1.36    0.17

Scr, serum creatinine; BUN, blood urea nitrogen; UAER, urinary albumin excretion rate; ACR, albumin-to-creatinine ratio; hs-CRP, hypersensitive C-reactive protein; IL-6, Interleukin-6; MDA, malondialdehyde.

Publication Bias {#s3_8}
----------------

Due to the lack of studies (\< 10), we did not perform the publication bias analysis.

Discussion {#s4}
==========

Salvianolate, derived from the extract of *Salvia miltiorrhiza*, is the first Chinese medicine preparation with pharmacokinetic parameters in humans and has the highest content of active ingredients in *Salvia miltiorrhiza* preparations ([@B19]). Modern clinical studies demonstrated that salvianolate is mainly used in cardiocerebral vascular diseases, because its main component salvia magnesium acetate has anti-lipid peroxidation properties and can improve endothelial function. Furthermore, it plays an important role in the prevention and treatment of some metabolic diseases ([@B11]; [@B52]; [@B33]). Recently, studies on the active components of TCM received increasing interest, particularly those that meet the new therapeutic targets of DN.

DN is a chronic disease characterized by the thickening of the glomerular basement membrane and the accumulation of extracellular matrix on the basis of renal hyperfiltration and highperfusion, eventually leading to renal failure ([@B29]). According to the theory of TCM, microvascular diseases belong to the category of "collateral disease". Following the viewpoints of "chronic diseases transforming to collaterals" ("jiu bing ru luo") and " chronic diseases being stasis" ("jiu bing cheng yu"), it is particularly important to promote blood circulation and eliminate blood stasis ([@B18]). Coincidentally, salvianolate activates blood circulation, removes stasis, and dredges pulse. These effects not only conform with the TCM treatment principle, but have also been supported by modern pharmacology ([@B45]). Salvianolate has antioxidative properties, inhibits inflammation, and improves microcirculation, thereby exhibiting protective effects to kidneys. These pharmacological activities exert their effects through multiple targets and links ([@B17]).

To our knowlwdge, this is the first systematic review to comprehensively assess the relation between salvianolate and DN. Our meta-analysis included 12 RCTs with a total of 1030 patients suffering from DN. According to the pooled data analysis, compared with western medicine monotherapy, the combination of salvianolate and western medicine is more effective in reducing Scr, BUN, UAER, 24h Upro, ACR, hs-CRP, IL-6, and MDA levels, and improving SOD levels and clinical efficacy. Thus, all these results indicated that the combination therapy had a stronger effect in treating DN, as its action on protecting renal function, inhibiting inflammation, and performing antioxidation.

Complicated pathogenesis makes diagnosis and treatment of DN difficult. Fortunately, existing biomarkers can help understand its progression and drug therapeutic effects. Among the multiple biomarkers for evaluating DN, improved renal function reflects the drug's kidney-protective mechanism to a certain extent. Scr and BUN are typical indicators of renal function and provide important information for kidney injury, of which Scr is also recommended by Kidney Disease Improving Global Outcomes (KDIGO) guideline ([@B47]; [@B57]). In addition to reflecting the function of glomerular filtration, Scr and BUN levels can also indicate improvement in renal prognosis ([@B24]). The reduction in their levels from our meta-analysis illustrated that salvianolate may paly a part in renoprotection. However, high heterogeneity of the results cannot be ignored. Subgroup analysis of Scr according to DN stage found no difference in stage III. This might be explained by an insignificant change with Scr levels in early DN. Besides, the stage of DN may be one of the sources because of the declined heterogeneity for both Scr and BUN in subgroup analyses. Proteinuria is another clinical hallmark that contributes to progression of DN ([@B44]). It is thought to be more specific than total proteinuria for a glomerular source, and is often used as the standard for defining the presence of DN ([@B6]). Earlier studies have showed that microalbuminuria (\> 300 mg/24 h of albuminuria) is predictive of the further development of end-stage renal failure and cardiovascular diseases ([@B12]). Consequently, treatments that reduce proteinuria can preserve renal function in DN patients. In this study, UAER and 24h Upro as the major indexes of proteinuria were chosen for data analysis. Our results revealed that the combined application of salvianolate and western medicine had better efficacy in decreasing UAER and 24h Upro. However, we failed to find the cause of heterogeneity in UAER after conducting subgroup analysis and sensitivity analysis. Possible reasons may be related to factors such as age, sex, type of diabetes, disease course, and treatment duration. Although no heterogeneity existed in 24h Upro, the accuracy for collecting 24-hour urine was poor, which may increase the risk of bias. Thus, in clinical practice, the detection of ACR can be performed with random urine which reduces errors, was recommended to estimate renal function ([@B56]). The results of our study showed significant reduced ACR in salvianolate and western medicine combination. Despite the considerate heterogeneity, it is hard to investigate the sources owing to the small number of patients. Thus, trials with larger sample sizes are required.

Furthermore, experimental research showed that patients affected with DN have varying degrees of inflammatory response and oxidative stress, whose mechanisms can serve as potential targets for long-term DN therapies ([@B5]). Potential biomarkers were emerging during the last years. hs-CRP is an acute phase protein sensitive to inflammation. In DN patients, the increase in hs-CRP levels is associated with increased IL-6 synthesis, because persistent hyperglycemia can stimulate islet cells to produce IL-6, which then acts on the liver and secretes hs-CRP in large quantities ([@B43]). SOD is the first line of defense against reactive oxygen species, which promote superoxide anion radicals to damage kidney tissues ([@B25]). MDA is a metabolite of prostaglandins that is generated through lipid peroxidation and increased free radicals caused by hyperglycemia and hyperlipidemia ([@B40]). Based on the 12 studies, we found that the salvianolate combined with western medicine exerts beneficial effects in controlling inflammation and antioxidation. Due to heterogeneity, sensitive analyses were conducted in terms of hs-CRP, IL-6, and MDA. Unfortunately, the origin of heterogeneity remained unknown for IL-6. However, for hs-CRP, we found the cause may be linked to the study [@B28] with the longest diabetes duration. For MDA, the results of insignificant *P*-value with the removed study [@B22] was not sufficient to draw a conclusion because of the small sample. Therefore, the effects of salvianolate in combination with western medicine on DN should be interpreted with caution. Moreover, salvianolate seems to be safe because of the absence of evident adverse reactions during treatment. Nevertheless, only 41.7% of the studies reported adverse reactions, the safety of salvianolate still needs to be validated in the future clinical trials.

Limitations {#s4_1}
-----------

Limitations in our meta-analysis should be considered as follows: First of all, literatures were included with low quality and small sample sizes. And the research methods were not reported in details, thereby making bias risk assessment difficult. Particularly, none of the studies provided any detail on single or double blinding, and allocation concealment, which indicated poor quality of methodology and led to high risk of selection and measurement bias. Secondly, although we adopted an adequate search strategy to minimize publication bias, some potential biases may still exist because of language restriction. Thirdly, drug safety is a key factor in clinical applications, but only five RCTs described adverse reactions or events. Therefore, the safety of using salvianolate should be validated in future to bring more convincing evidence. Fourthly, all the involved DN patients were in stage III ang IV, the effect of salvianolate on end-stage DN is uncertain and needs to be proved. Besides, none of the studies reported end-point outcomes such as the incidence of ESRD, fatality rate, and life quality, thus making the assessment of the long-term efficacy of salvianolate difficult, which will affect the further development of drugs. Lastly, the considerable heterogeneity observed mostly emerged in continuous variables such as Scr and BUN. It was difficult to find the real sources of heterogeneity, and we speculated that the causes may be relevant to sample size, research object, and the assessment method of outcomes.

Conclusions {#s5}
===========

Findings from this meta-analysis illustrate that salvianolate combined with western medicine may be effective and safe in the treatment of DN. Because of the poor methodological quality and small sample sizes, further validation is essential. Therefore, we recommend the conduct of multicenter, large-sample, and randomized controlled double-blind trials to provide a more accurate and reliable evidence for clinical research.
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